Fidelis Diagnostics Limited 10804605 false 2023-07-01 2024-06-30 2024-06-30 The principal activity of the company is medical practice activities Digita Accounts Production Advanced 6.30.9574.0 true true 10804605 2023-07-01 2024-06-30 10804605 2024-06-30 10804605 core:RetainedEarningsAccumulatedLosses 2024-06-30 10804605 core:ShareCapital 2024-06-30 10804605 core:CurrentFinancialInstruments 2024-06-30 10804605 core:CurrentFinancialInstruments core:WithinOneYear 2024-06-30 10804605 core:OfficeEquipment 2024-06-30 10804605 core:PlantMachinery 2024-06-30 10804605 bus:SmallEntities 2023-07-01 2024-06-30 10804605 bus:AuditExemptWithAccountantsReport 2023-07-01 2024-06-30 10804605 bus:FilletedAccounts 2023-07-01 2024-06-30 10804605 bus:SmallCompaniesRegimeForAccounts 2023-07-01 2024-06-30 10804605 bus:RegisteredOffice 2023-07-01 2024-06-30 10804605 bus:Director1 2023-07-01 2024-06-30 10804605 bus:Director2 2023-07-01 2024-06-30 10804605 bus:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 10804605 core:OfficeEquipment 2023-07-01 2024-06-30 10804605 core:PlantMachinery 2023-07-01 2024-06-30 10804605 core:ParentEntities 2023-07-01 2024-06-30 10804605 1 2023-07-01 2024-06-30 10804605 countries:EnglandWales 2023-07-01 2024-06-30 10804605 2023-06-30 10804605 core:OfficeEquipment 2023-06-30 10804605 core:PlantMachinery 2023-06-30 10804605 2022-07-01 2023-06-30 10804605 2023-06-30 10804605 core:RetainedEarningsAccumulatedLosses 2023-06-30 10804605 core:ShareCapital 2023-06-30 10804605 core:CurrentFinancialInstruments 2023-06-30 10804605 core:CurrentFinancialInstruments core:WithinOneYear 2023-06-30 10804605 core:OfficeEquipment 2023-06-30 10804605 core:PlantMachinery 2023-06-30 iso4217:GBP xbrli:pure

Registration number: 10804605

Fidelis Diagnostics Limited

Unaudited Filleted Financial Statements

for the Year Ended 30 June 2024

 

Fidelis Diagnostics Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 6

 

Fidelis Diagnostics Limited

Company Information

Directors

V S Shrivastava

R N Tiam

Registered office

Kingfisher Court
Plaxton Bridge Road
Woodmansey
Beverley
HU17 0RT

 

Fidelis Diagnostics Limited

(Registration number: 10804605)
Balance Sheet as at 30 June 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

4

491

1,402

Current assets

 

Debtors

5

61

1,579

Cash at bank and in hand

 

13,072

102,576

 

13,133

104,155

Creditors: Amounts falling due within one year

6

(5,165)

(9,629)

Net current assets

 

7,968

94,526

Total assets less current liabilities

 

8,459

95,928

Provisions for liabilities

(93)

(266)

Net assets

 

8,366

95,662

Capital and reserves

 

Called up share capital

100

100

Retained earnings

8,266

95,562

Shareholders' funds

 

8,366

95,662

For the financial year ending 30 June 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the Company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the Directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 13 March 2025 and signed on its behalf by:
 

.........................................
V S Shrivastava
Director

.........................................
R N Tiam
Director

 

Fidelis Diagnostics Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024

1

General information

The company is a private company limited by share capital incorporated in England and Wales and the company registration number is 10804605.

The address of its registered office is:
Kingfisher Court
Plaxton Bridge Road
Woodmansey
Beverley
HU17 0RT

The principal place of business is:
Spire Hull and East Riding Hospital
Lowfield Road
Hull
HU10 7AZ

These financial statements were authorised for issue by the Board on 13 March 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The financial statements have been prepared in sterling and are rounded to the nearest pound.

Summary of disclosure exemptions

The company has taken advantage of exemption under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' not to disclose related party transactions with it's parent. Group accounts have not been prepared under the FRS102 section 1a disclosure exemption applicable to small groups..

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the provision of healthcare services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

 

Fidelis Diagnostics Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax represents the future tax consequences of transactions and events recognised in the financial statements of current and previous periods. It is recognised in respect of all timing differences, with certain exceptions. Timing differences are differences between taxable profits and total comprehensive income as stated in the financial statements that arise from the inclusion of income and expense in tax assessments in periods different from those in which they are recognised in the financial statements. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date that are expected to apply to the reversal of timing differences. Deferred tax on revalued non-depreciable tangible fixed assets and investment properties is measured using the rates and allowances that apply to the sale of the asset.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

At each reporting date fixed assets are reviewed to determine whether there is any indication that those assets have suffered an impairment loss. If there is an indication of possible impairment, the recoverable amount of any affected asset is estimated and compared with its carrying amount. If the estimated recoverable amount is lower, the carrying amount is reduced to its estimated recoverable amount, and an impairment loss is recognised immediately in the profit and loss account.

If an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but not in excess of the amount that would have been determined had no impairment loss has been recognised for the asset in prior years. A reversal of an impairment loss is recognised immediately in the profit and loss account.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office equipment

20% Straight line

Plant and machinery

20% Straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

 

Fidelis Diagnostics Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024

Dividends

Dividend distribution to the Company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the Company (including Directors) during the year, was 2 (2023 - 2).

4

Tangible assets

Plant and machinery
£

Office equipment
£

Total
£

Cost or valuation

At 1 July 2023

2,300

2,656

4,956

At 30 June 2024

2,300

2,656

4,956

Depreciation

At 1 July 2023

1,840

1,714

3,554

Charge for the year

460

451

911

At 30 June 2024

2,300

2,165

4,465

Carrying amount

At 30 June 2024

-

491

491

At 30 June 2023

460

942

1,402

5

Debtors

2024
£

2023
£

Prepayments

61

1,579

61

1,579

 

Fidelis Diagnostics Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024

6

Creditors

Creditors: amounts falling due within one year

Note

2024
£

2023
£

Due within one year

 

Loans and borrowings

7

1,539

1,485

Taxation and social security

 

3,303

7,814

Accruals and deferred income

 

323

330

 

5,165

9,629

7

Loans and borrowings

2024
£

2023
£

Current loans and borrowings

Other borrowings

1,539

1,485


Other borrowings relates to an unsecured directors loan account.

8

Related party transactions

Other transactions with Directors

At the year end, the amount due to the directors was £1,539 (2023: £1,485). This amount is unsecured, interest free and repayable on demand.

Summary of transactions with parent

The company has taken advantage of exemption under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' not to disclose related party transactions with it's parent. Group accounts have not been prepared under the FRS102 section 1a disclosure exemption applicable to small groups.
 

9

Parent and ultimate parent undertaking

The Company's immediate parent is Octavian Holdings Limited, incorporated in United Kingdom.

  These financial statements are available upon request from 41 Elveley Drive, West Ella, East Yorkshire, HU10 7RT.